

Thomas N Kakuda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/888728/publications.pdf>

Version: 2024-02-01

74
papers

2,955
citations

212478

28
h-index

190340

53
g-index

78
all docs

78
docs citations

78
times ranked

2439
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. <i>Clinical Therapeutics</i> , 2000, 22, 685-708.	1.1	545
2	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. <i>Aids</i> , 2002, 16, 551-560.	1.0	133
3	The Cellular Pharmacology of Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors and Its Relationship to Clinical Toxicities. <i>Clinical Infectious Diseases</i> , 2004, 38, 743-753.	2.9	127
4	Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?. <i>Current Opinion in Infectious Diseases</i> , 2000, 13, 5-11.	1.3	121
5	Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. <i>Aids</i> , 2003, 17, 2159-2168.	1.0	121
6	Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. <i>Aids</i> , 1999, 13, 2311.	1.0	120
7	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , 2019, 156, 1392-1403.e7.	0.6	115
8	Zidovudine triphosphate and lamivudine triphosphate concentration response relationships in HIV-infected persons. <i>Aids</i> , 2000, 14, 2137-2144.	1.0	103
9	Clinical Pharmacokinetics and Pharmacodynamics of Etravirine. <i>Clinical Pharmacokinetics</i> , 2009, 48, 561-574.	1.6	101
10	Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4228-4232.	1.4	94
11	Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers. <i>Antiviral Therapy</i> , 2007, 12, 789-796.	0.6	91
12	Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2011, 50, 25-39.	1.6	70
13	Mitochondrial toxic effects and ribavirin. <i>Lancet, The</i> , 2001, 357, 1802-1803.	6.3	66
14	Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 236-242.	1.4	62
15	Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. <i>AIDS Research and Therapy</i> , 2014, 11, 39.	0.7	58
16	A pharmacokinetic study of etravirine (TMC125) coadministered with ranitidine and omeprazole in HIV negative volunteers. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 508-516.	1.1	50
17	Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. <i>HIV Medicine</i> , 2014, 15, 50-56.	1.0	49
18	Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 949-957.	1.0	44

#	ARTICLE	IF	CITATIONS
19	Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine. <i>Pharmacotherapy</i> , 2008, 28, 1215-1222.	1.2	39
20	Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naïve HIV type-1-infected adults. <i>Antiviral Therapy</i> , 2010, 15, 711-720.	0.6	37
21	Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. <i>Antiviral Therapy</i> , 2014, 19, 597-606.	0.6	36
22	Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV-Negative Volunteers. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 322-329.	1.0	35
23	Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. <i>Contraception</i> , 2009, 80, 44-52.	0.8	35
24	Drug Interactions between HIV Protease Inhibitors and Acid-Reducing Agents. <i>Clinical Pharmacokinetics</i> , 2008, 47, 75-89.	1.6	33
25	Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2290-2296.	1.4	32
26	Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2008, 13, 655-661.	0.6	32
27	Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. <i>HIV Medicine</i> , 2009, 10, 173-181.	1.0	29
28	Pharmacokinetics of Elvitegravir and Etravirine following Coadministration of Ritonavir-Boosted Elvitegravir and Etravirine. <i>Antiviral Therapy</i> , 2008, 13, 1011-1017.	0.6	29
29	Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2591-2605.	1.3	27
30	Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. <i>AAPS Journal</i> , 2019, 21, 1.	2.2	27
31	Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. <i>Antiviral Therapy</i> , 2010, 15, 817-829.	0.6	26
32	Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers. <i>Annals of Pharmacotherapy</i> , 2008, 42, 757-765.	0.9	25
33	Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	0.3	25
34	Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. <i>Antiviral Therapy</i> , 2007, 12, 789-96.	0.6	25
35	Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1-infected Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 940-945.	1.1	23
36	Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. <i>HIV Medicine</i> , 2013, 14, 421-429.	1.0	21

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women. <i>HIV Medicine</i> , 2016, 17, 643-652.	1.0	20
38	Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers. <i>Pharmacotherapy</i> , 2006, 26, 1060-1068.	1.2	17
39	The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 422-431.	1.0	17
40	Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. <i>HIV Medicine</i> , 2014, 15, 513-524.	1.0	17
41	Pharmacokinetics of Saquinavir With Atazanavir or Low-Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 201-208.	1.0	15
42	Safety and Efficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e132-e137.	1.1	14
43	Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. <i>Aids</i> , 2012, 26, 447-455.	1.0	13
44	Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 563-573.	1.0	13
45	Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2663-2672.	1.1	13
46	Drug Interactions with New and Investigational Antiretrovirals. <i>Clinical Pharmacokinetics</i> , 2010, 49, 67-68.	1.6	12
47	Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 728-734.	1.3	12
48	The INST1001 study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects. <i>HIV Medicine</i> , 2015, 16, 288-296.	1.0	12
49	Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2008, 13, 655-61.	0.6	12
50	Darunavir/cobicistat once daily for the treatment of HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 691-704.	2.0	11
51	Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 202-210.	1.0	10
52	Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 346-352.	0.8	9
53	Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged 3 to 12 Years. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 406-414.	1.3	9
54	Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. <i>Antiviral Therapy</i> , 2008, 13, 1011-7.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antiviral Therapy, 2010, 15, 803-816.	0.6	8
56	Pharmacokinetics and Shortâ€Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIVâ€Negative Volunteers. Journal of Clinical Pharmacology, 2013, 53, 41-50.	1.0	8
57	Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 805-816.	0.3	8
58	Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine. Clinical Pharmacokinetics, 2017, 56, 525-536.	1.6	8
59	Shortâ€Duration ALâ€335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. Hepatology, 2018, 68, 2145-2157.	3.6	8
60	Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 725-736.	0.3	8
61	Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-NaÃve Patients. HIV Clinical Trials, 2013, 14, 92-98.	2.0	7
62	JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antiviral Therapy, 2022, 27, 135965352210938.	0.6	7
63	Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. Journal of Antimicrobial Chemotherapy, 2006, 58, 220-221.	1.3	6
64	Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment, 2015, 2015, 1-11.	0.3	6
65	Pharmacokinetics, safety, and tolerability of the 2â€and 3â€directâ€acting antiviral combination of <sc>AL</sc>â€335, odalasvir, and simeprevir in healthy subjects. Pharmacology Research and Perspectives, 2018, 6, e00395.	1.1	5
66	Reply to Stevens et al. Clinical Infectious Diseases, 2004, 39, 878-879.	2.9	4
67	Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research, 2010, 8, 564-576.	0.2	4
68	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIVâ€1â€Infected, Treatmentâ€Experienced Children and Adolescents in PIANO. Journal of Clinical Pharmacology, 2016, 56, 1395-1405.	1.0	4
69	Optimizing dosing strategies for the combination of atazanavir plus saquinavir. Aids, 2004, 18, 704-705.	1.0	3
70	Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy, 2021, 26, 13-24.	0.6	2
71	Design of antiretroviral drug interaction studies. Current Opinion in HIV and AIDS, 2008, 3, 313-318.	1.5	1
72	Antiretroviral drug interactions. , 2005, , 305-318.		0

#	ARTICLE	IF	CITATIONS
73	Antiretroviral drug interactions. , 0, , 360-381.		0
74	Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach. AAPS Journal, 2018, 20, 111.	2.2	0